Results from the FINE-HEART pooled analysis of three Phase 3 clinical trials highlight the potential of finerenone in treating patients with high-risk cardiovascular disease.
Kerendia reduces cardiovascular mortality in patients with cardiac, renal and metabolic diseases
Leave a comment
